BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Recaticimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Recaticimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07062328-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Recaticimab: Phase 2 readout est. (NCT07062328)
DESCRIPTION:Recaticimab\, phase 2.\nStudy: A Trial of Recaticimab and Adebr
 elimab in Combination With Chemotherapy in Patients With Unresectable BTC\
 nEstimated primary completion: 10 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/recaticimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07062328
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002476-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Recaticimab: Phase 3 readout est. (NCT07002476)
DESCRIPTION:Recaticimab\, phase 3.\nStudy: Early Aggressive Strategy for Tr
 eatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovasc
 ular Therapy for Large Artery Occlusion\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/recaticima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 002476
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373847-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Recaticimab: Phase 4 readout est. (NCT07373847)
DESCRIPTION:Recaticimab\, phase 4\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Vunakizumab Combined With Recaticimab in Subjects With Moderate t
 o Severe Plaque Psoriasis and Dyslipidemia\nEstimated primary completion: 
 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/recatic
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07373847
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290699-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Recaticimab: Phase 4 readout est. (NCT07290699)
DESCRIPTION:Recaticimab\, phase 4.\nStudy: Intensive Cholesterol-Lowering W
 ithin 24 Hours of PCI Perioperative Period\nEstimated primary completion: 
 30 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/recat
 icimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07290699
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674368-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Recaticimab: Phase 4 readout est. (NCT07674368)
DESCRIPTION:Recaticimab\, phase 4\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholest
 erolemia / Mixed\nEstimated primary completion: 10 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/recaticimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07674368
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605130-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Recaticimab: Phase 4 readout est. (NCT07605130)
DESCRIPTION:Recaticimab\, phase 4.\nStudy: Efficacy and Safety Study of Dig
 ital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strate
 gy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial
 \, Randomized\, Parallel-Group\, Multicenter Trial\nEstimated primary comp
 letion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/recaticimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07605130
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567326-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Recaticimab: Phase 2 readout est. (NCT07567326)
DESCRIPTION:Recaticimab\, phase 2.\nStudy: Adebrelimab or Retlirafusp Alfa 
 Plus Recaticimab and Chemotherapy for Resectable NSCLC\nEstimated primary 
 completion: December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/recaticimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07567326
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07119918-1051@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Recaticimab: Phase 3 readout est. (NCT07119918)
DESCRIPTION:Recaticimab\, phase 3.\nStudy: PCSK9 Inhibitor for Intracranial
  Atherosclerotic Symptomatic Stenosis\nEstimated primary completion: 1 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/recaticim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7119918
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
